A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
- Resource Type
- Abstract
- Authors
- LaBarbera, Kelsie M.; Sheline, Yvette I.; Izzo, Nicholas J.; Yuede, Carla M.; Waybright, Lora; Yurko, Raymond; Edwards, Hannah M.; Gardiner, Woodrow D.; Blennow, Kaj; Zetterberg, Henrik; Börjesson-Hanson, Anne; Morgan, Roger; Davis, Charles S.; Guttendorf, Robert J.; Schneider, Lon S.; DeKosky, Steven; LeVine III, Harry; Grundman, Michael; Caggiano, Anthony O.; Cirrito, John R.
- Source
- Translational Neurodegeneration. 5/12/2023, Vol. 12 Issue 1, p1-4. 4p.
- Subject
- *ALZHEIMER'S disease
*CLINICAL trials
*IMPLANTABLE catheters
*LEWY body dementia
*RETENTION of urine
*CEREBROSPINAL fluid shunts
- Language
- ISSN
- 2047-9158
The selective increase in CSF A oligomers but not monomers in the two patients with CT1812 treatment is consistent with preclinical evidence that CT1812 selectively displaces oligomeric over monomeric A [[3]]. Eligibility criteria for the study included a diagnosis of mild-moderate AD (Mini-Mental State Examination score 18-26) and either an AD-positive amyloid positron emission tomography scan or a positive CSF result for AD biomarkers (Additional file 1) within 12 months before or at screening. The observed selective increase in CSF A oligomers also suggests that there is a displaceable pool of A oligomers in the AD central nervous system and provides early evidence that the mechanism of action of CT1812 elucidated preclinically translates to the clinic. A phase 1b randomized clinical trial of CT1812 to measure A oligomer displacement in Alzheimer's disease using an indwelling CSF catheter. [Extracted from the article]